去势前列腺癌患者睾酮检测:去势切点适用性与现行免疫分析准确性
研究分析120例经LHRH激动剂去势的前列腺癌患者余留血清,用五种方法(四种自动化免疫分析及LC-MS/MS)检测睾酮。所有方法得出的去势上限均显著低于现行1.7 nmol/L切点,且自动化免疫分析与LC-MS/MS回归斜率范围为1.4至3.8,所有免疫分析均未达到基于生物学变异的总误差要求。
要点
- 现行1.7 nmol/L去势切点可能偏高,各方法95%上限均显著低于该值。
- 自动化免疫分析与LC-MS/MS的回归斜率差异大,Access斜率高达3.8。
- 所有自动化免疫分析均未满足基于生物学变异的总误差标准。
核心结论
- 较低的去势睾酮切点可能更适合评估前列腺癌去势充分性。
- 现行自动化免疫分析在去势前列腺癌患者中缺乏定量准确度。
研究设计与样本
- 研究分析了120例经LHRH激动剂去势的前列腺癌患者余留血清。
- 采用五种方法检测睾酮:Architect i2000、Access、Cobas 6000、Atellica及LC-MS/MS。
主要发现
- 各方法去势95%上限范围为0.472 nmol/L(LC-MS/MS)至1.25 nmol/L(Access),均显著低于1.7 nmol/L。
- 自动化免疫分析与LC-MS/MS的Passing-Bablok回归斜率范围为1.4(Cobas和Atellica)至3.8(Access)。
- Architect与LC-MS/MS相关性最高(ρ=0.58)。
- 所有自动化免疫分析均未达到基于生物学变异的总误差要求。
关键数值与推荐
- 现行去势切点为1.7 nmol/L(50 ng/dL),基于共识而非验证。
- 去势95%上限:LC-MS/MS为0.472 nmol/L,Access为1.25 nmol/L。
- Passing-Bablok回归斜率:Cobas和Atellica为1.4,Access为3.8。
临床怎么用
- 评估去势充分性时需注意现行1.7 nmol/L切点可能偏高。
- 使用自动化免疫分析定量去势患者低浓度睾酮时,应关注其分析准确性不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Testosterone testing is relevant for evaluating castration adequacy and diagnosis of castration-resistant prostate cancer (PCa). However, the recommended testosterone cut-off of 1.7 nmol/L (50 ng/dL) to define adequate castration is based on consensus and not validated for the automated immunoassays (AIA) used in today's medical laboratories. Furthermore, appropriate population intervals have not been determined by a state-of-the-art assay. We investigated the analytical suitability of this cut-off and the accuracy of the present-day AIAs for testosterone analysis in castrated PCa patients. METHODS: Leftover serum from 120 PCa patients castrated with luteinizing hormone-releasing hormone agonists was analysed for testosterone by five methods: Architect i2000 (Abbott), Access (Beckman), Cobas 6000 (Roche), Atellica (Siemens), LC-MS/MS. For all assays, the castration 95th, 97.5th and 99th percentile upper limits were determined. Furthermore, Passing-Bablok regression, mean bias and Spearman's correlation coefficients were compared to the LC-MS/MS method and total error based on biological variation. RESULTS: All castration upper limits, ranging from 0.472 nmol/L (LC-MS/MS) to 1.25 nmol/L (Access) (95% percentile), were significantly lower than the current castration cut-off (1.7 nmol/L). Slopes of Passing-Bablok regressions comparing the AIA with the LC-MS/MS method ranged from 1.4 (Cobas and Atellica) to 3.8 (Access). The Architect showed the highest correlation with LC-MS/MS (ρ=0.58). All AIA failed to meet the desirable total error criterion. CONCLUSIONS: These results suggest that a lower general testosterone castration cut-off may be more appropriate in evaluating the adequacy of castration in PCa and that present-day AIA lack analytical accuracy to quantify testosterone levels in castrated PCa.
引用
- van Winden LJ, Lentjes EGWM, Demir AY, et al. Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays. Clin Chem Lab Med. 2022. PMID: 35918785. doi:10.1515/cclm-2022-0506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。